Abstract
A recent E-Rare workshop reviewed the ethical aspects of whole exome and whole genome-sequencing studies (WES and WGS, respectively) in rare diseases. Leveraging new genomic technologies, which output vast amounts of known and novel genetic variants, researchers are learning more about the genetic basis and mechanisms involved in rare diseases. In some cases, these findings are translated into diagnostic tools for the benefit of rare disease patients. Among the disclosed data, which can assist in treatment management, incidental findings await, bringing with them ethical concerns for the clinicians, researchers and patients. © 2013 Cambridge University Press.
Cite
CITATION STYLE
Farberov, L., Gilam, A., Isakov, O., & Shomron, N. (2013). Meeting summary: Ethical aspects of whole exome and whole genome sequencing studies (WES/WGS) in rare diseases, Tel Aviv, Israel, January 2013. Genetics Research, 95(2–3), 53–56. https://doi.org/10.1017/S0016672313000104
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.